Beginning yesterday, the agency's card programme is providing increased support for colorectal cancer, lung cancer, multiple myeloma, Parkinson's disease, and thyroid disease.

Source: https://jamaica-star.com/article/news/20231026/five-new-health-conditions-added-nhf-card-programme

Cecelia Brunott, 46, from Surrey, was diagnosed with myeloma in 2020 and has been taking lenalidomide since September 2021, following a bone marrow transplant.

Source: https://www.dailymail.co.uk/health/article-11875811/Scientists-develop-gene-test-tell-blood-cancer-drugs-work.html?ns_mchannel=rss&ns_campaign=1490&ito=1490

GC012F is currently being studied in multiple investigator-initiated trials (IIT) evaluating its safety and efficacy in RRMM, newly-diagnosed multiple myeloma, and B-cell non-Hodgkin's lymphoma.

Source: https://www.marketscreener.com/quote/stock/GRACELL-BIOTECHNOLOGIES-I-117317674/news/Gracell-Biotechnologies-Announces-FDA-Clearance-of-the-IND-Application-for-Phase-1b-2-Clinical-Trial-42890341/?utm_medium=RSS&utm_content=20230203

He said: 24,000 people in the UK have myeloma, so that’s one hour on my feet for every 1000 people.

Source: https://redditchstandard.co.uk/news/redditch-businessman-raises-over-2000-for-blood-cancer-charity/

Turning to Slide 14, our GPRC5D targeting CAR-T is a potential first-in-class agent in relapse or refractory multiple myeloma.

Source: https://seekingalpha.com/article/4609793-bristol-myers-squibb-company-bmy-presents-2023-virtual-asco-investor-event-conference?source=feed_all_articles